EDSA - Edesa Biotech Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Capital Market Current Price & Safety Score Price: 2.63 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): -7.83 StockBond Score: -3.20 Company Description Edesa Biotech Inc is a biopharmaceutical firm focused on discovering developing and commercializing clinicalstage treatments for inflammatory and immune system disorders where current medical options are inadequate The companys key pipeline assets include EB05 a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome ARDS in COVID19 patients and EB01 a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis Furthermore Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10 This company was established in 2015 and is based in Markham Canada